Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 0904-6506

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 0904-6506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

04fef048 A63e 46e9 9fc4 Afdd4aae775b 00

Memantine Hydrochloride Tablets, USP 10 mg film-coated oral tablets by Major Pharmaceuticals. The label shows the unit dose container with 100 tablets. It includes storage instructions at 20°-25°C, dispensing directions, and a note to keep out of reach of children. Distributed by Major Pharmaceuticals in Livonia, MI, USA.*

FDA Label Image

04fef048 A63e 46e9 9fc4 Afdd4aae775b 01

Memantine Hydrochloride 5 mg Unit Dose film-coated tablets label from Major Pharmaceuticals. It indicates the product is for oral use, contains 100 tablets, and is prescription-only. The label includes dosing and storage instructions as well as distributor and manufacturer information.*

FDA Label Image

Figure1

A line graph showing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Placebo and Memantine Hydrochloride. The y-axis ranges from clinical improvement to clinical decline, while the x-axis indicates time in weeks. Memantine HCl shows less decline compared to placebo over time.*

FDA Label Image

Figure2

A line graph comparing the cumulative percentage of patients over changes from baseline in ADCS-ADL scores for Placebo and Memantine Hydrochloride groups. The x-axis represents the ADCS-ADL change from baseline and the y-axis shows the cumulative percentage of patients, illustrating treatment effects in a clinical study.*

FDA Label Image

Figure3

A line graph showing the mean change from baseline in SIB scores over 28 weeks of treatment, comparing Memantine Hydrochloride and placebo. The chart includes error bars and indicates clinical improvement and decline thresholds along the vertical axis.*

FDA Label Image

Figure4

A line graph showing the cumulative percentage of patients on the vertical axis versus SIB (Severe Impairment Battery) change from baseline on the horizontal axis. The graph compares two groups labeled Placebo and Memantine HCl, with Memantine HCl showing a higher cumulative percentage of patients improving at various SIB change points.*

FDA Label Image

Figure5

A line graph comparing mean ADCS-ADL scores over 24 weeks of treatment between two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The X-axis represents weeks of treatment, and the Y-axis represents mean change from baseline in the ADCS-ADL score, with annotations for clinical improvement and clinical decline. Error bars indicate standard error of the mean for each data point.*

FDA Label Image

Figure6

A line graph depicting the cumulative percentage of patients versus ADCS-ADL change from baseline. Two treatment groups are shown: Placebo/Donepezil and Memantine HCl/Donepezil, illustrating patient response over a range of baseline changes.*

FDA Label Image

Figure7

A line graph depicting the mean change from baseline E.Cog scores over 24 weeks of treatment. It compares two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows the mean change from baseline E.Cog score, ranging from -4 to 4. The graph includes error bars and labels indicating clinical improvement and clinical decline areas.*

FDA Label Image

Figure8

A cumulative percentage graph showing patient response to treatments measured by SIB Change from Baseline. The graph compares Placebo/Donepezil versus Memantine HCl/Donepezil, with percentage of patients on the vertical axis and SIB change on the horizontal axis.*

FDA Label Image

Structure

Chemical structure of Memantine Hydrochloride, showing the molecular framework with amine and hydrochloride components clearly labeled.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.